Breaking News Instant updates and real-time market news.

RTRX

Retrophin

$21.50

0.23 (1.08%)

17:02
03/01/17
03/01
17:02
03/01/17
17:02

Retrophin down 3.2% after plans for Phase 3 trial before sparsentan filing

  • 01

    Mar

RTRX Retrophin
$21.50

0.23 (1.08%)

11/11/16
LEER
11/11/16
NO CHANGE
LEER
Outperform
Retrophin agreement for RE-024 bodes well for approval in 2019, says Leerink
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.
11/21/16
LEER
11/21/16
NO CHANGE
LEER
Outperform
Retrophin DUET data reintroduces accelerated approval optionality, says Leerink
Leerink analyst Joseph Schwartz says full DUET Phase 2b results for Retrophin's sparsentan in focal segmental glomerulosclerosis presented at the American Society of Nephrology Kidney Week meeting look "very strong" in terms of the ability of the drug to produce modified partial remissions and even some complete remissions during the 8-week double blind period. The analyst believes the "strong data" provides the company with as good an argument as ever to discuss the potential of accelerated approval with the FDA, although he notes that predicting FDA is "tough." He reiterates an Outperform rating on the shares.
11/21/16
BMOC
11/21/16
NO CHANGE
BMOC
Retrophin price target raised to $46 from $40 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company provided data on its Sparsentan treatment that the analyst views as positive. Kim now sees a 55% chance that the drug will be approved, up from 45% previously. The analyst continues to believe that the FDA might not accept proteinuria as an endpoint, but sees "growing evidence for proteinuria as a surrogate to kidney survival." Kim keeps an Outperform rating on the stock.
12/15/16
JMPS
12/15/16
NO CHANGE
JMPS
Experts support quick approval of Retrophin sparsentan, says JMP Securities
JMP Securities analyst Liisa Bayko says the firm's survey of experts who participated in the Phase 2 study of Retrophin's sparsentan in focal segmental glomerulosclerosis "showed strong support for accelerated approval" of the drug. Bayko reiterates a $28 price target and an Outperform rating on the shares of Retrophin.

TODAY'S FREE FLY STORIES

CAFD

8point3 Energy

$14.94

0.04 (0.27%)

, PEGI

Pattern Energy

$22.13

0.14 (0.64%)

15:46
11/20/17
11/20
15:46
11/20/17
15:46
Periodicals
8point3 draws interest from Capital Dynamics, Pattern Energy, Bloomberg says »

Capital Dynamics and…

CAFD

8point3 Energy

$14.94

0.04 (0.27%)

PEGI

Pattern Energy

$22.13

0.14 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

VRX

Valeant

$15.64

0.95 (6.47%)

15:40
11/20/17
11/20
15:40
11/20/17
15:40
Options
Valeant calls active as shares see relative strength »

Valeant calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jun

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

, GIS

General Mills

$54.23

0.51 (0.95%)

15:34
11/20/17
11/20
15:34
11/20/17
15:34
Periodicals
General Mills, not Nestle, should buy Hain Celestial, Cramer says »

Following a Bloomberg…

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

GIS

General Mills

$54.23

0.51 (0.95%)

NSRGY

Nestle

$85.11

0.7 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$156.55

0.9 (0.58%)

15:34
11/20/17
11/20
15:34
11/20/17
15:34
Options
Intuit options imply 5.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SHPG

Shire

$147.37

2.74 (1.89%)

, RHHBY

Roche

$29.10

0.205 (0.71%)

15:32
11/20/17
11/20
15:32
11/20/17
15:32
Recommendations
Shire, Roche analyst commentary  »

Shire selloff on Roche…

SHPG

Shire

$147.37

2.74 (1.89%)

RHHBY

Roche

$29.10

0.205 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 23

    Dec

  • 23

    Feb

15:30
11/20/17
11/20
15:30
11/20/17
15:30
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

TWX

Time Warner

$87.93

-0.79 (-0.89%)

15:28
11/20/17
11/20
15:28
11/20/17
15:28
Technical Analysis
Technical View: Time Warner drops on pending antitrust briefing »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.74

0.23 (0.67%)

, TWX

Time Warner

$87.93

-0.79 (-0.89%)

15:28
11/20/17
11/20
15:28
11/20/17
15:28
Periodicals
DOJ antitrust announcement concerns AT&T, Time Warner, NBC reports »

Bloomberg also reported…

T

AT&T

$34.74

0.23 (0.67%)

TWX

Time Warner

$87.93

-0.79 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

MRVL

Marvell

$20.29

0.03 (0.15%)

, CAVM

Cavium

$75.83

-0.47 (-0.62%)

15:27
11/20/17
11/20
15:27
11/20/17
15:27
Recommendations
Marvell, Cavium, Broadcom analyst commentary  »

Marvell price target…

MRVL

Marvell

$20.29

0.03 (0.15%)

CAVM

Cavium

$75.83

-0.47 (-0.62%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 06

    Dec

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

15:24
11/20/17
11/20
15:24
11/20/17
15:24
Technical Analysis
Technical View: Hain Celestial spikes higher, retraces some gains »

The shares have come off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

, NSRGY

Nestle

$85.11

0.7 (0.83%)

15:22
11/20/17
11/20
15:22
11/20/17
15:22
Hot Stocks
Hain Celestial surges after report of Nestle weighing potential bid »

Shares of Hain Celestial…

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

NSRGY

Nestle

$85.11

0.7 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$56.11

1.07 (1.94%)

15:20
11/20/17
11/20
15:20
11/20/17
15:20
Options
Sarepta Therapeutics sees a bullish option play »

Sarepta Therapeutics sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

HAIN

Hain Celestial

$40.06

0.21 (0.53%)

15:19
11/20/17
11/20
15:19
11/20/17
15:19
Hot Stocks
Breaking Hot Stocks news story on Hain Celestial »

Hain Celestial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRG

HRG Group

$16.06

-0.025 (-0.16%)

15:19
11/20/17
11/20
15:19
11/20/17
15:19
Options
Harbinger options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

, NSRGY

Nestle

$85.11

0.7 (0.83%)

15:17
11/20/17
11/20
15:17
11/20/17
15:17
Hot Stocks
Breaking Hot Stocks news story on Hain Celestial, Nestle »

Hain Celestial jumps 7%,…

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

NSRGY

Nestle

$85.11

0.7 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
11/20/17
11/20
15:17
11/20/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
11/20/17
11/20
15:16
11/20/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$85.11

0.7 (0.83%)

, HAIN

Hain Celestial

$39.84

1.35 (3.51%)

15:16
11/20/17
11/20
15:16
11/20/17
15:16
Periodicals
Breaking Periodicals news story on Nestle, Hain Celestial »

Nestle looking into bid…

NSRGY

Nestle

$85.11

0.7 (0.83%)

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRNCY

Cairn Energy

$5.63

0.3383 (6.39%)

, BP

BP

$39.10

0.01 (0.03%)

15:14
11/20/17
11/20
15:14
11/20/17
15:14
Periodicals
BP in talks to buy 30% SNE field stake from Cairn Energy, Reuters reports »

Cairn Energy (CRNCY) is…

CRNCY

Cairn Energy

$5.63

0.3383 (6.39%)

BP

BP

$39.10

0.01 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$39.98

0.13 (0.33%)

15:14
11/20/17
11/20
15:14
11/20/17
15:14
Hot Stocks
Breaking Hot Stocks news story on Hain Celestial »

Hain Celestial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.76

0.25 (0.72%)

, TWX

Time Warner

$88.62

-0.1 (-0.11%)

15:12
11/20/17
11/20
15:12
11/20/17
15:12
Periodicals
U.S. to hold briefing today on 'significant antitrust matter,' Bloomberg says »

Shares of AT&T (T)…

T

AT&T

$34.76

0.25 (0.72%)

TWX

Time Warner

$88.62

-0.1 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

NBRV

Nabriva Therapeutics

$5.80

0.05 (0.87%)

15:10
11/20/17
11/20
15:10
11/20/17
15:10
Options
Notable call buying in Nabriva Therapeutics »

Notable call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLMN

Bloomin' Brands

$18.27

0.49 (2.76%)

15:07
11/20/17
11/20
15:07
11/20/17
15:07
Hot Stocks
Bloomin' Brands jumps after Jana reports stake, says may push for sale »

Shares of Bloomin'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAME

Atlantic American Corp

$3.60

-0.05 (-1.37%)

15:06
11/20/17
11/20
15:06
11/20/17
15:06
Hot Stocks
Atlantic American Corp names Ross Franklin as CFO »

Atlantic American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$9.24

-0.545 (-5.57%)

15:04
11/20/17
11/20
15:04
11/20/17
15:04
Options
Vipshop options imply 13.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.